Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg-42.9 mg/ 5 mL Oral Suspension Under Fed Conditions
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the rate and extent of absorption of Ranbaxy
Laboratories Limited, India, Amoxicillin-Clavulanic acid and GlaxoSmithKline, U.S.A.
(Augmentin ES-600), amoxicillin-clavulanic acid, administered as a 1 x 5 mL (600 mg - 42.9
mg) oral suspension, under fed conditions.